---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-26-001254"
form_type: "8-K"
ticker: "LPCN"
cik: "0001535955"
company_name: "Lipocine Inc."
filed_at: "2026-01-12T23:59:59+00:00"
generated_at: "2026-05-16T10:51:30.917522+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Lipocine: Phase 3 PPD trial passes second DSMB safety review; topline data due Q2 2026

## Summary
- DSMB reviewed safety data from 82 randomized patients; recommended trial continue without modification.
- No drug discontinuations, excessive sedation, loss of consciousness, or drug-related SAEs reported.
- Study no longer screening new participants; still enrolling eligible patients.
- Topline safety and efficacy results expected early Q2 2026; data to support NDA submission.
- CEO cites confidence in safety profile; potential for new treatment paradigm.

## SEC filing metadata
- accession: 0001493152-26-001254
- form_type: 8-K
- ticker: LPCN
- cik: 0001535955
- company_name: Lipocine Inc.
- filed_at: 2026-01-12T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1535955/000149315226001254/0001493152-26-001254-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1535955/000149315226001254/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-26-001254
- JSON: https://secwatch.observer/filing/0001493152-26-001254.json
- Plain text: https://secwatch.observer/filing/0001493152-26-001254.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.